Progyny stock has climbed strongly in the near term and reached a fresh 52 week high, yet there is a clear split in what the valuation checks say, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to sizable upside while earnings based multiples suggest the shares already trade at a premium. Over 5 years, Progyny has delivered a decline of 43.1%, which means long term holders have not yet shared in the recent momentum. Upgraded analyst views and a stronger earnings outlook...

Earlier this week, several Wall Street firms issued upbeat research on Progyny, highlighting stronger June activity and signaling increased confidence in its upcoming earnings and guidance. This wave of positive analyst commentary underscores how closely investors are watching Progyny’s operating trends as a gauge of employer demand for fertility and family-building benefits. Next, we’ll examine how rising analyst optimism about June transaction trends could influence Progyny’s existing...

Check out the companies making headlines yesterday:

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 3.5% in the afternoon session after KeyBanc raised its price target on the stock to $35 from $30, citing expectations of a strong earnings report and increased future guidance.